keyword
https://read.qxmd.com/read/38642484/disruption-of-nmda-receptor-mediated-regulation-of-ppi-in-the-maternal-immune-activation-model-of-schizophrenia-is-restored-by-17%C3%AE-estradiol-and-raloxifene
#1
JOURNAL ARTICLE
Andrea Gogos, Alyssa Sbisa, Maarten van den Buuse
Maternal immune activation (MIA) during pregnancy is known to increase the risk of development of schizophrenia in the offspring. Sex steroid hormone analogues have been proposed as potential antipsychotic treatments but the mechanisms of action involved remain unclear. Estrogen has been shown to alter N-methyl-d-aspartate (NMDA) receptor binding in the brain. We therefore studied the effect of chronic treatment with 17β-estradiol, its isomer, 17α-estradiol, and the selective estrogen receptor modulator, raloxifene, on MIA-induced psychosis-like behaviour and the effect of the NMDA receptor antagonist, MK-801...
April 19, 2024: Schizophrenia Research
https://read.qxmd.com/read/38638417/effects-of-systemic-pretreatment-with-the-naaladase-inhibitor-2-pmpa-on-oral-methamphetamine-reinforcement-in-c57bl-6j-mice
#2
JOURNAL ARTICLE
Elissa K Fultz, Andrea Y T Nei, Joyce C Chi, Jacqueline N Lichter, Karen K Szumlinski
INTRODUCTION: Repeated exposure to methamphetamine (MA) in laboratory rodents induces a sensitization of glutamate release within the corticoaccumbens pathway that drives both the rewarding and reinforcing properties of this highly addictive drug. Such findings argue the potential for pharmaceutical agents inhibiting glutamate release or its postsynaptic actions at glutamate receptors as treatment strategies for MA use disorder. One compound that may accomplish both of these pharmacological actions is the N -acetylated-alpha-linked-acidic dipeptidase (NAALADase) inhibitor 2-(phosphonomethyl)pentanedioic acid (2-PMPA)...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38638036/n-methyl-d-aspartate-nmda-receptor-antagonists-and-their-pharmacological-implication-a-medicinal-chemistry-oriented-perspective-outline
#3
JOURNAL ARTICLE
Vikas Rana, Shayantan Ghosh, Akanksha Bhatt, Damini Bisht, Gaurav Joshi, Priyank Purohit
N-methyl-D-aspartate (NMDA) receptors, i.e., inotropic glutamate receptors, are important in synaptic plasticity, brain growth, memory, and learning. The activation of NMDA is done by neurotransmitter glutamate and co-agonist (glycine or D-serine) binding. However, the over-activation of NMDA elevates the intracellular calcium influx, which causes various neurological diseases and disorders. Therefore, to prevent excitotoxicity and neuronal death, inhibition of NMDA must be done using its antagonist. This review delineates the structure of subunits of NMDA and the conformational changes induced after the binding of agonists (glycine and D-serine) and antagonists (ifenprodil, etc...
April 17, 2024: Current Medicinal Chemistry
https://read.qxmd.com/read/38631821/postnatal-hypofunction-of-n-methyl-d-aspartate-receptors-alters-perforant-path-synaptic-plasticity-and-filtering-and-impairs-dentate-gyrus-mediated-spatial-discrimination
#4
JOURNAL ARTICLE
Luis A Márquez, Carolina López Rubalcava, Emilio J Galván
BACKGROUND AND PURPOSE: Transient hypofunction of the NMDA receptor represents a convergence point for the onset and further development of psychiatric disorders, including schizophrenia. Although the cumulative evidence indicates dysregulation of the hippocampal formation in schizophrenia, the integrity of the synaptic transmission and plasticity conveyed by the somatosensorial inputs to the dentate gyrus, the perforant pathway synapses, have barely been explored in this pathological condition...
April 17, 2024: British Journal of Pharmacology
https://read.qxmd.com/read/38631682/ketamine-use-for-palliative-care-in-the-austere-environment-is-ketamine-the-path-forward-for-palliative-care
#5
JOURNAL ARTICLE
John R Reed, Stephanie K Parks, Antony Kaniaru, Justin Hefley, Young Yauger, Jeremy V Edwards, Derrick C Glymph
The goal of palliative care is to focus on the holistic needs of the patient and their family versus the pathology of the patient's diagnosis to reduce the stress of illness. U.S. servicemembers deployed to austere environments worldwide have significantly less access to palliative care than in military treatment facilities in the U.S. Preparation for future conflicts introduces the concept of prolonged medical management for an environment where urgent casualty evacuation is impossible. Ketamine is currently widely used for analgesia and anesthesia in the care of military service members and its use has increased in combat zones of Iraq and Afghanistan due to the favorable preservation of respiratory function, minimal changes in hemodynamics, and lower pain scores compared to opioids...
April 17, 2024: American Journal of Hospice & Palliative Care
https://read.qxmd.com/read/38617266/ketamine-can-produce-oscillatory-dynamics-by-engaging-mechanisms-dependent-on-the-kinetics-of-nmda-receptors
#6
Elie Adam, Marek Kowalski, Oluwaseun Akeju, Earl K Miller, Emery N Brown, Michelle M McCarthy, Nancy Kopell
Ketamine is an NMDA-receptor antagonist that produces sedation, analgesia and dissociation at low doses and profound unconsciousness with antinociception at high doses. At high and low doses, ketamine can generate gamma oscillations ( > 25 Hz) in the electroencephalogram (EEG). The gamma oscillations are interrupted by slow-delta oscillations (0.1-4 Hz) at high doses. Ketamine's primary molecular targets and its oscillatory dynamics have been characterized. However, how the actions of ketamine at the subcellular level give rise to the oscillatory dynamics observed at the network level remains unknown...
April 5, 2024: bioRxiv
https://read.qxmd.com/read/38612229/an-exploration-of-analgesia-options-for-australian-sheep
#7
REVIEW
Shari Cohen, Emily Foss, Thierry Beths, Gabrielle C Musk
During their lifetime, sheep undergo many painful husbandry and disease processes. Procedures undertaken on the farm, such as tail docking, castration, and mulesing, all cause considerable pain. In addition, sheep may experience painful diseases and injuries that require treatment by veterinary practitioners, and in biomedical research, sheep may undergo painful experimental procedures or conditions. It is important due to ethics, animal welfare, social licence, and, at times, legal requirements for farmers, veterinary practitioners, and researchers to provide pain relief for animals in their care...
March 22, 2024: Animals: An Open Access Journal From MDPI
https://read.qxmd.com/read/38598639/structure-and-function-of-glun1-3a-nmda-receptor-excitatory-glycine-receptor-channel
#8
JOURNAL ARTICLE
Kevin Michalski, Hiro Furukawa
N -methyl-d-aspartate receptors (NMDARs) and other ionotropic glutamate receptors (iGluRs) mediate most of the excitatory signaling in the mammalian brains in response to the neurotransmitter glutamate. Uniquely, NMDARs composed of GluN1 and GluN3 are activated exclusively by glycine, the neurotransmitter conventionally mediating inhibitory signaling when it binds to pentameric glycine receptors. The GluN1-3 NMDARs are vital for regulating neuronal excitability, circuit function, and specific behaviors, yet our understanding of their functional mechanism at the molecular level has remained limited...
April 12, 2024: Science Advances
https://read.qxmd.com/read/38596207/ketamine-infusion-in-a-resistant-obsessive-compulsive-disorder-patient-in-bangladesh-with-severe-suicidal-ideation-a-case-report
#9
Sultana Algin, Debasish Banik, Sm Atikur Rahman, Saiful Mahmud Tusher, Fatema Tuj Johora, Asha Akter, Tanbir Ahmed, Md Abdul Monib Biswas, Susmita Sinha, Mainul Haque
Treatment of resistant obsessive-compulsive disorder (OCD) typically results in insufficient symptom alleviation, and even long-term medication often fails to have the intended effect. Ketamine is a potent non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. Studies have shown that low-dose ketamine infusion results in a considerable reduction in obsessive-compulsive symptoms and a rapid resolution of suicidal ideation. This is a case report on the effect of intravenous ketamine infusion on a patient with resistant OCD and severe suicidal ideation...
April 2024: Curēus
https://read.qxmd.com/read/38586442/review-on-anti-alzheimer-drug-development-approaches-challenges-and-perspectives
#10
REVIEW
Abdallah E Abdallah
Alzheimer is an irreversible progressive neurodegenerative disease that causes failure of cerebral neurons and disability of the affected person to practice normal daily life activities. There is no concrete evidence to identify the exact reason behind the disease, so several relevant hypotheses emerged, highlighting many possible therapeutic targets, such as acetylcholinesterase, cholinergic receptors, N -methyl d-aspartate receptors, phosphodiesterase, amyloid β protein, protein phosphatase 2A, glycogen synthase kinase-3 beta, β-secretase, γ-secretase, α-secretase, serotonergic receptors, glutaminyl cyclase, tumor necrosis factor-α, γ-aminobutyric acid receptors, and mitochondria...
April 3, 2024: RSC Advances
https://read.qxmd.com/read/38585463/low-affinity-nmda-receptor-antagonist-hemantane-in-a-topical-formulation-attenuates-arthritis-induced-by-freund-s-complete-adjuvant-in-rats
#11
JOURNAL ARTICLE
Elena Ivanova, Alexander Matyushkin, Alexandra Sorokina, Svetlana Alexeeva, Irina Miroshkina, Kirill Kachalov, Tatyana Voronina, Andrey Durnev
PURPOSE: N-methyl-D-aspartate (NMDA) receptors that are expressed by T-cells modulate T-cell proliferation, cytotoxicity and cell migration toward chemokines. Several studies have shown an anti-inflammatory effect of NMDA receptor antagonists. This study compares the effect of the noncompetitive low-affinity NMDA receptor antagonist N-(2-adamantyl)-hexamethyleneimine hydrochloride (hemantane) in a topical formulation (gel) with the cyclooxygenase (COX) inhibitor diclofenac in a topical formulation (gel) in rats with arthritis induced by Freund's Complete Adjuvant (FCA)...
March 2024: Advanced Pharmaceutical Bulletin
https://read.qxmd.com/read/38574646/particulate-matter-pm-10-exacerbates-on-mk-801-induced-schizophrenia-like-behaviors-through-the-inhibition-of-erk-creb-bdnf-signaling-pathway
#12
JOURNAL ARTICLE
Seung-Hyuk Choi, Ho Jung Bae, So-Yeon Kim, Tamanna Jahan Mony, Hyun-Jeong Kim, Ye Eun Cho, Yu-Yeong Choi, Ju-Yeon An, So-Young Cho, Dong Hyun Kim, Se Jin Park
Particulate matter (PM), released into the air by a variety of natural and human activities, is a key indicator of air pollution. Although PM is known as the extensive health hazard to affect a variety of illness, few studies have specifically investigated the effects of PM10 exposure on schizophrenic development. In the present study, we aimed to investigate the impact of PM10 on MK-801, N-methyl-D-aspartate (NMDA) receptor antagonist, induced schizophrenia-like behaviors in C57BL/6 mouse. Preadolescent mice were exposed PM10 to 3...
April 3, 2024: Ecotoxicology and Environmental Safety
https://read.qxmd.com/read/38562734/convergent-effects-of-different-anesthetics-are-due-to-changes-in-phase-alignment-of-cortical-oscillations
#13
Alexandra G Bardon, Jesus J Ballesteros, Scott L Brincat, Jefferson E Roy, Meredith K Mahnke, Yumiko Ishizawa, Emery N Brown, Earl K Miller
Many different anesthetics cause loss of responsiveness despite having diverse underlying molecular and circuit actions. To explore the convergent effects of these drugs, we examined how ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, and dexmedetomidine, an α2 adrenergic receptor agonist, affected neural oscillations in the prefrontal cortex of nonhuman primates. Previous work has shown that anesthesia increases phase locking of low-frequency local field potential activity across cortex...
March 20, 2024: bioRxiv
https://read.qxmd.com/read/38561605/a-review-of-the-common-neurodegenerative-disorders-current-therapeutic-approaches-and-the-potential-role-of-bioactive-peptides
#14
JOURNAL ARTICLE
Kuldeep Singh, Jeetendra Kumar Gupta, Shivendra Kumar, Urvashi Soni
Neurodegenerative disorders, which include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), represent a significant and growing global health challenge. Current therapies predominantly focus on symptom management rather than altering disease progression. In this review, we discuss the major therapeutic strategies in practice for these disorders, highlighting their limitations. For AD, the mainstay treatments are cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists...
March 29, 2024: Current Protein & Peptide Science
https://read.qxmd.com/read/38561071/impact-of-nmda-receptors-block-versus-gaba-a-receptors-modulation-on-synaptic-plasticity-and-brain-electrical-activity-in-metabolic-syndrome
#15
JOURNAL ARTICLE
Shaimaa Nasr Amin, Sherif Ahmed Shaltout, Walaa Bayoumie El Gazzar, Noha Samir Abdel Latif, Ghada Al-Jussani, Yasmeen Jamal Alabdallat, Khaled Anwer Albakri, Dalia Azmy Elberry
PURPOSE: Metabolic syndrome (MetS) is a common disorder associated with disturbed neurotransmitter homeostasis. Memantine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, was first used in Alzheimer's disease. Allopregnanolone (Allo), a potent positive allosteric modulator of the Gamma-Amino-Butyric Acid (GABA)-A receptors, decreases in neurodegenerative diseases. The study investigated the impact of Memantine versus Allo administration on the animal model of MetS to clarify whether the mechanism of abnormalities is related more to excitatory or inhibitory neurotransmitter dysfunction...
March 30, 2024: Advances in Medical Sciences
https://read.qxmd.com/read/38555116/substitution-therapy-for-patients-with-alcohol-dependence-mechanisms-of-action-and-efficacy
#16
JOURNAL ARTICLE
Julien Guiraud, Rainer Spanagel, Wim van den Brink
New approaches for the treatment of alcohol dependence (AD) may improve patient outcomes. Substitution maintenance therapy is one of the most effective treatment options for opioid and nicotine use disorders. So far, there has been little attention to substitution therapy for the treatment of AD. Here, we explain the mechanistic foundations of alcohol substitution maintenance therapy. Alcohol has many primary targets in the brain (and other organs) and the physical interaction of ethanol molecules with these specific ethanol-sensitive sites on a variety of ionotropic receptors (e...
2024: International Review of Neurobiology
https://read.qxmd.com/read/38555114/current-treatments-of-alcohol-use-disorder
#17
JOURNAL ARTICLE
Tommaso Dionisi, Giovanna Di Sario, Lorenzo De Mori, Giorgia Spagnolo, Mariangela Antonelli, Claudia Tarli, Luisa Sestito, Francesco Antonio Mancarella, Daniele Ferrarese, Antonio Mirijello, Gabriele Angelo Vassallo, Antonio Gasbarrini, Giovanni Addolorato
Emerging treatments for alcohol dependence reveal an intricate interplay of neurobiological, psychological, and circumstantial factors that contribute to Alcohol Use Disorder (AUD). The approved strategies balancing these factors involve extensive manipulations of neurotransmitter systems such as GABA, Glutamate, Dopamine, Serotonin, and Acetylcholine. Innovative developments are engaging mechanisms such as GABA reuptake inhibition and allosteric modulation. Closer scrutiny is placed on the role of Glutamate in chronic alcohol consumption, with treatments like NMDA receptor antagonists and antiglutamatergic medications showing significant promise...
2024: International Review of Neurobiology
https://read.qxmd.com/read/38551038/nanomedicine-a-new-frontier-in-alzheimer-s-disease-drug-targeting
#18
JOURNAL ARTICLE
Kalyani Pathak, Mohammad Zaki Ahmad, Riya Saikia, Manash Pratim Pathak, Jon Jyoti Sahariah, Parimita Kalita, Aparoop Das, Md Ariful Islam, Pallab Pramanik, Dubom Tayeng, Basel A Abdel-Wahab
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder affecting elderly individuals, characterized by progressive cognitive decline leading to dementia. This review examines the challenges posed by anatomical and biochemical barriers such as the blood-brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB), and p-glycoproteins in delivering effective therapeutic agents to the central nervous system (CNS) for AD treatment. This article outlines the fundamental role of acetylcholinesterase inhibitors (AChEIs) and NMDA(N-Methyl-D-Aspartate) receptor antagonists in conventional AD therapy and highlights their limitations in terms of brain-specific delivery...
March 28, 2024: Central Nervous System Agents in Medicinal Chemistry
https://read.qxmd.com/read/38543300/useful-role-of-a-new-generation-of-dexamethasone-vitamin-e-and-human-serum-albumin-microparticles-in-the-prevention-of-excitotoxicity-injury-in-retinal-ocular-diseases
#19
JOURNAL ARTICLE
Javier Rodríguez Villanueva, Pedro de la Villa, Rocío Herrero-Vanrell, Irene Bravo-Osuna, Manuel Guzmán-Navarro
Excitotoxicity has been linked to the pathogenesis of several serious degenerative ocular diseases. Long-term overactivation of the NMDA receptor by glutamate in retinal ganglion cells (RGCs) results in degeneration, apoptosis and loss of function leading to blindness. NMDA receptor antagonists have been proposed as a pharmacological blockage of glutamate excitotoxicity. However, an inhibition of the pathway activated by glutamate receptors has intolerable side effects. An interesting pharmacological alternative would be the use of antiapoptotic compounds as RGCs' neuroprotective active substances...
March 15, 2024: Pharmaceutics
https://read.qxmd.com/read/38525254/hype-or-hope-high-placebo-response-in-major-depression-treatment-with-ketamine-and-esketamine-a-systematic-review-and-meta-analysis
#20
Alexandros Matsingos, Marcel Wilhelm, Laila Noor, Cüneyt Yildiz, Winfried Rief, Stefan G Hofmann, Irina Falkenberg, Tilo Kircher
BACKGROUND: Ketamine and esketamine offer a novel approach in the pharmacological treatment of major depressive disorder (MDD). This meta-analysis aimed to investigate the placebo response in double-blind, randomized controlled studies (RCTs) on patients with MDD receiving ketamine or esketamine. METHODS: For this systematic review and meta-analysis Medline (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), PsycInfo and Embase databases were systematically searched for citations published up to March 17, 2023...
2024: Frontiers in Psychiatry
keyword
keyword
53188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.